PJ.2.1, a new SARS-CoV-2 variant first detected in a sample taken in Ontario, Canada, on 2 May 2026, has spread to several continents; WHO said in early November 2026 that it is tracking it.
It is a 'saltation' variant — one that carries an unusually large set of mutations at once — descended from MC.10.1.7, a JN.1-lineage virus.
A Journal of Infection study (October 2026) found improved ACE2 binding and cell entry, but no major escape from antibodies raised by the LP.8.1-adapted mRNA vaccine.
WHO says there is no clinical evidence that PJ.2.1 causes more severe disease than other variants; symptoms resemble a cold or flu.
Most variants evolve by small step-wise mutations. A saltation variant appears with many mutations at once, often from long chronic infections, so it can differ sharply in its spike protein. BA.2.86 ('Pirola', 2023), the ancestor of JN.1, was the best-known earlier example.
Simple Analogy: Skipping several rungs of a ladder in one leap.
Classifies SARS-CoV-2 variants into three tiers — Variant Under Monitoring (VUM), Variant of Interest (VOI) and Variant of Concern (VOC, the highest)
India's network of genome-sequencing laboratories tracking SARS-CoV-2 variants; set up in December 2020 under the Union Health Ministry with the Department of Biotechnology and ICMR
Saltation variant BA.2.86 detected; it gives rise to JN.1
WHO designates JN.1 a Variant of Interest
First documented PJ.2.1 sample collected in Ontario, Canada
Journal of Infection publishes the first virological characterisation of PJ.2.1
WHO says it is tracking PJ.2.1 as it spreads across continents
GS Paper III > Science & Technology > Biotechnology, Health
General Awareness > Science > Diseases
Angiotensin-converting enzyme 2 — the human cell-surface receptor that the SARS-CoV-2 spike protein binds to for entry.
A variant that arrives with many mutations at once rather than accumulating them gradually.
WHO's lowest tier for a variant with changes that may matter but whose impact is still unclear.